HIV drug resistance showdown: stay or switch?
NCT ID NCT06747507
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This trial looks at what to do when the HIV virus becomes resistant to the drug dolutegravir. It compares staying on dolutegravir versus switching to another drug combination (darunavir/ritonavir) to see which better lowers the virus level. About 392 people with HIV and specific resistance mutations will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dolutegravir pill or darunavir+ritonavir pill
What this could lead to
If it works, this could show the best way to manage HIV when the virus becomes resistant to dolutegravir, helping more people achieve viral suppression.
What could go wrong
This is a Phase 3 trial, but it only includes people with specific resistance mutations, so results may not apply to everyone. There is also a risk that neither strategy works well.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bomu Hospital
NOT_YET_RECRUITINGMombasa, Kenya
Contact
-
Butha-Buthe District Hospital
NOT_YET_RECRUITINGButha-Buthe, Lesotho
Contact
-
CS Machava II
NOT_YET_RECRUITINGMaputo, Mozambique
Contact
-
CS Ndlavela
NOT_YET_RECRUITINGMaputo, Mozambique
Contact
-
CS Ponta Gea
NOT_YET_RECRUITINGBeira, Sofala, Mozambique
Contact
-
Jaramogi Oginga Odinga Teaching and Referral Hospital
RECRUITINGKisumu, Kenya
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kenyatta National Hospital
RECRUITINGNairobi, 00100, Kenya
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MUHAS Clinical Trial Unit
NOT_YET_RECRUITINGDar es Salaam, Tanzania
Contact
-
Mokhotlong District Hospital
NOT_YET_RECRUITINGMokhotlong, Lesotho
Contact